Prof. Fabio Pacelli
  • Chi sono
  • Patologie trattate
    • Patologia oncologica
    • Patologia benigna
  • Pubblicazioni
  • Videogallery
  • Dicono di me
  • Prenota una visita
  • Chi sono
  • Patologie trattate
    • Patologia oncologica
    • Patologia benigna
  • Pubblicazioni
  • Videogallery
  • Dicono di me
  • Prenota una visita

/Pubblicazioni/Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy.

Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy.

By Prof. Fabio Pacelli - In Pubblicazioni - 28 Maggio 2012

Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e191-5. Epub 2012 Feb 22.

Ippolito E, Massaccesi M, Digesù C, Deodato F, Macchia G, Pirozzi GA, Cilla S, Cuscunà D, Di Lallo A, Mattiucci GC, Mantini G, Pacelli F, Valentini V, Cellini N, Ingrosso M, Morganti AG.

Radiotherapy Unit, Fondazione di Ricerca e Cura Giovanni Paolo II, Università Cattolica del S. Cuore, Campobasso, Italy.

PURPOSE:
To predict the grade and incidence of late clinical rectal toxicity through short-term (1 year) mucosal alterations.

METHODS AND MATERIALS:
Patients with prostate adenocarcinoma treated with curative or adjuvant radiotherapy underwent proctoscopy a year after the course of radiotherapy. Mucosal changes were classified by the Vienna Rectoscopy Score (VRS). Late toxicity data were analyzed according to the Kaplan-Meier method. Comparison between prognosis groups was performed by log-rank analysis.

RESULTS:
After a median follow-up time of 45 months (range, 18-99), the 3-year incidence of grade ?2 rectal late toxicity according to the criteria of the European Organization for Research and Treatment of Cancer and the Radiation Therapy Oncology Group was 24%, with all patients (24/24; 100%) experiencing rectal bleeding. The occurrence of grade ?2 clinical rectal late toxicity was higher in patients with grade ?2 (32% vs. 15 %, p = 0.02) or grade ?3 VRS telangiectasia (47% vs. 17%, p ? 0.01) and an overall VRS score of ?2 (31% vs. 16 %, p = 0.04) or ?3 (48% vs. 17%, p = 0.01) at the 1-year proctoscopy.

CONCLUSIONS:
Early proctoscopy (1 year) predicts late rectal bleeding and therefore can be used as a surrogate endpoint for late rectal toxicity in studies aimed at reducing this frequent complication.

Copyright © 2012 Elsevier Inc. All rights reserved.

Torna alle pubblicazioni

Share

  • Google+
  • Twitter
  • Facebook
← A very advanced case of a T cell peritoneal lymphomatosis.
Short-Course Accelerated Radiotherapy in Palliative Treatment of Advanced Pelvic Malignancies: A Phase I Study. →

Ultimi articoli

  • Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis
    Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis

    Surgical Oncology; 2020 34:270-275. Di G...

  • Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin
    Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin

    International Journal of Surgery Case Re...

  • Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma
    Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma

    Therapeutic Advances in Medical Oncology...

  • Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies using new hybrid CO2 system: preliminary experience in referral center
    Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies using new hybrid CO2 system: preliminary experience in referral center

    Updates in Surgery; 2019 71:555-560. Cia...

  • The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer‚ a randomized-controlled trial
    The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer‚ a randomized-controlled trial

    Gastric Cancer; 2019 22:632-639. Bencini...

Archivi

  • Febbraio 2021
  • Febbraio 2018
  • Gennaio 2018
  • Novembre 2016
  • Ottobre 2016
  • Luglio 2013
  • Maggio 2012

CONTATTI

Prof. Fabio Pacelli
E-mail: fabio.pacelli@policlinicogemelli.it

Policlinico Universitario "A. Gemelli"
Direttore UOC Chirurgia del peritoneo e del retroperitoneo
Largo F. Vito, 1 - 00168 Roma
Tel. (+39) 06 30157255

PRENOTA UNA VISITA

Visite private - Tel. (+39) 06 88818881

Visite online - Videoconsulto@policlinicogemelli.it

In alternativa utilizza la nostra FORM DI CONTATTO per inviarci un messaggio

Copyright © 2012-. All Rights Reserved - Powered by Apiweb Srl